Incomplete and ambiguous ethnicity category labels limited equity-focused analyses ... Initially, services were for monitoring patients with stable glaucoma, age-related macular degeneration and ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration <li /> Designat ...

The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related macular ...

Because we do not understand aging well, we may hesitate to really get to know older adults and minister to them.

The field of gerontology is witnessing a significant demographic transition, as the global population of individuals aged 65 ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...